Raleigh Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-25
| Closed | -$2.68K | – | 830 |
|
|
2024
Q4 | $2.68K | Hold |
25
| – | – | ﹤0.01% | 804 |
|
|
2024
Q3 | $2.5K | Hold |
25
| – | – | ﹤0.01% | 790 |
|
|
2024
Q2 | $2.11K | Hold |
25
| – | – | ﹤0.01% | 777 |
|
|
2024
Q1 | $1.83K | Hold |
25
| – | – | ﹤0.01% | 776 |
|
|
2023
Q4 | $1.79K | Hold |
25
| – | – | ﹤0.01% | 878 |
|
|
2023
Q3 | $1.5K | Sell |
25
-60
| -71% | -$3.6K | ﹤0.01% | 798 |
|
|
2023
Q2 | $6.13K | Buy |
85
+22
| +35% | +$1.59K | ﹤0.01% | 602 |
|
|
2023
Q1 | $4.63K | Buy |
63
+38
| +152% | +$2.8K | ﹤0.01% | 621 |
|
|
2022
Q4 | $1.67K | Sell |
25
-15
| -38% | -$1K | ﹤0.01% | 699 |
|
|
2022
Q3 | $2K | Hold |
40
| – | – | ﹤0.01% | 659 |
|
|
2022
Q2 | $2K | Hold |
40
| – | – | ﹤0.01% | 542 |
|
|
2022
Q1 | $3K | Buy |
+40
| New | +$3K | ﹤0.01% | 520 |
|